Responsiveness to change to change due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer

被引:10
作者
Lemieux, Julie [1 ]
Beaton, Dorcas E.
Hogg-Johnson, Sheilah
Bordeleau, Louise J.
Hunter, Jon
Goodwin, Pamela J.
机构
[1] Univ Laval, Ctr Hosp, Hop St Sacrement, Ctr Rech,Unite Rech Sante Populat, Quebec City, PQ G1S 4LB, Canada
[2] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada
[3] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada
[4] Univ Quebec, Ctr Hosp, Unite Rech Sante Populat, Dept Hematol, Quebec City, PQ, Canada
基金
加拿大健康研究院;
关键词
responsiveness to change; supportive-expressive group therapy; questionnaires; quality of life; metastatic breast cancer;
D O I
10.1007/s11136-007-9208-2
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective To compare the responsiveness of six questionnaires using three hypotheses of change: (i) change due to supportive-expressive group therapy (SEGT), (ii) improved mood defined as a small effect size (.2) on Profile of Mood States (POMS) Total Mood Disturbance score and (iii) progression of disease. Method Data from the "Breast Expressive-Supportive Therapy" study, a multicentre randomized controlled trial of change due to SEGT versus standard of care in women with metastatic breast cancer were used. Questionnaires studied were: POMS, Impact of Event Scale, Psychosocial Adjustment to Illness Scale (PAIS), EORTC QLQ-C30, Mental Adjustment to Cancer and a Pain visual analog scale (VAS). Responsiveness to change was evaluated using the standardized response mean. POMS was used as the standard. Results POMS was the most responsive questionnaire to change due to SEGT. Questionnaires measuring psychosocial attributes were responsive to improvement in mood. EORTC QLQ-C30, PAIS, PAIN VAS and MAC were the most responsive to disease progression. More responsive questionnaires were associated with the smallest sample size required to detect an effect. Conclusions Responsiveness to change is context specific. The POMS was the most responsive questionnaire to psychosocial therapy.
引用
收藏
页码:1007 / 1017
页数:11
相关论文
共 46 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Changes in psychological distress of women in long-term remission from breast cancer in two different geographical settings: a randomized study [J].
Andritsch, E ;
Goldzweig, G ;
Samonigg, H ;
Uziely, B ;
Ever-Hadani, P ;
Hoffman, G ;
Krenn, G ;
Baider, L .
SUPPORTIVE CARE IN CANCER, 2004, 12 (01) :10-18
[3]   Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: Overall effects of the intervention and an exploration of missing data [J].
Bordeleau, L ;
Szalai, JP ;
Ennis, M ;
Leszcz, M ;
Speca, M ;
Sela, R ;
Doll, R ;
Chochinov, HM ;
Navarro, M ;
Arnold, A ;
Pritchard, KI ;
Bezjak, A ;
Llewellyn-Thomas, HA ;
Sawka, CA ;
Goodwin, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1944-1951
[4]   Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, investigational drug branch for breast cancer and the new drug development group study [J].
Bottomley, A ;
Biganzoli, L ;
Cufer, T ;
Coleman, RE ;
Coens, C ;
Efficace, F ;
Calvert, HA ;
Gamucci, T ;
Twelves, C ;
Fargeot, P ;
Piccart, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2576-2586
[5]   Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life [J].
Cella, D ;
Bullinger, M ;
Scott, C ;
Barofsky, I .
MAYO CLINIC PROCEEDINGS, 2002, 77 (04) :384-392
[6]  
Clark P, 2003, J RHEUMATOL, V30, P1584
[7]  
CLASSEN, 1993, BRIEF SUPPORTIVE EXP, P55
[8]   Supportive-expressive group therapy and distress in patients with metastatic breast cancer - A randomized clinical intervention trial [J].
Classen, C ;
Butler, LD ;
Koopman, C ;
Miller, E ;
DiMiceli, S ;
Giese-Davis, J ;
Fobair, P ;
Carlson, RW ;
Kraemer, HC ;
Spiegel, D .
ARCHIVES OF GENERAL PSYCHIATRY, 2001, 58 (05) :494-501
[9]  
Cohen J., 1988, POWERSTATISTICALSCIE, DOI 10.4324/9780203771587
[10]  
Cunningham AJ, 1998, PSYCHO-ONCOL, V7, P508, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<508::AID-PON376>3.0.CO